

Global Leukemia Antibodies Market, Drug Sales & Clinical Trials Insight 2028

<https://marketpublishers.com/r/GA589F953407EN.html>

Date: May 2022

Pages: 330

Price: US\$ 3,000.00 (Single User License)

ID: GA589F953407EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Leukemia Cancer Antibodies Market, Drug Sales and Clinical Trials Insight 2028
Report Highlights:

Leukemia Cancer Antibodies Market Global and Regional Outlook

Global Leukemia Cancer Antibodies Market Opportunity > USD 4 Billion

Global and Regional Sales Analysis

Leukemia Cancer Antibody Drug Conjugates, Monoclonal Antibodies, Bispecific Antibodies Insight

Pricing, Dosage, Patent Insight On Approved Leukemia Cancer Antibodies

Comprehensive Insight On More Than 100 Leukemia Cancer Antibodies in Clinical Trials

Leukemia Cancer Antibodies in Clinical Trials Insight By Phase, Company, Orphan Designation

Antibody therapeutics represents one of the most promising classes of immunotherapy which is designed to harness the potential of immune system in the targeting of cancer. These therapeutics have shown to significantly improve the survival rate in wide range

of cancers include leukemia and its various subtypes. Based on the rapidity of cell proliferation, leukemia can be classified as acute or chronic, and myeloid or lymphoid based on the originator cell. The dominant subtypes of leukemia are acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) which have shown increasing prevalence in the global population.

The genomic analysis has demonstrated high expression of CD20 and CD33 on the leukemic cells. Therefore, these receptors have emerged as promising druggable targets for the immunotherapeutic approaches. At present, a cocktail of monoclonal antibodies and antibody drug conjugates directed towards these receptors have entered the global market. Moreover, bispecific antibody targeting CD19 as well as CD3 has also been approved for the management of acute lymphoblastic leukemia. The encouraging response of this therapeutics has propelled the further research and development activities in this domain. Presently, more than 100 clinical trials are ongoing in global leukemia antibody therapeutics market.

US is currently holding the maximum number of clinical trials in the market which is mainly attributed to the presence of major key players in the region associated with their huge investments in this segment. For instance, Immunogen has developed IMGN632, which is a CD123 targeted antibody drug conjugate in clinical development for the management of acute myeloid leukemia. Researchers are evaluating the role of investigational drug in combination with Vidaza (azacitidine) and Venclexta® (venetoclax) (triplet) in patients with relapsed/ refractory (R/R) acute myeloid leukemia. The drug is present in initial stages of development and is expected to gain entry in market during the forecast period.

Apart from US, China is also making huge investments in antibody therapeutics to cope up with the market growth. The China pharmaceutical market is also expanding at large rates owing to presence of both domestic as well as international players. The growth is reliant on supportive government policies, favorable healthcare coverage rates, advancements in medical technology, and new product launches in the market. In 2020, National Medical Products Administration (NMPA) of China has announced the approval of Halpryza (rituximab injection). In addition, other key growth drivers for the market in China include the ageing trend of Chinese population, rising healthcare expenditure, and improving the public medical insurance system.

At present, therapeutic monoclonal antibodies are currently dominating the global market which is mainly attributed to large number of product approved, availability of cost effective biosimilars, and favorable reimbursement policies. However, it is

estimated that bispecific antibodies will emerge as potential therapeutic option in the management of leukemia owing to their enhanced efficacy and specificity in the management of disease. Although only one bispecific antibody has entered the market, their robust pipeline suggests that several bispecific antibodies will gain entry into the market during the forecast period, thus boosting this segment.

As per our report findings, the global leukemia antibody therapeutics market is expected to surpass US\$ 4 Billion by 2028. Several factors are boosting the growth of market including increasing burden of leukemia cases, high unmet medical need for cancer therapy and rising investment in healthcare sectors. Moreover, large number of investments made in this segment has enabled pharmaceutical companies to develop more enhanced antibody therapeutics for the management of leukemia. Many pharmaceutical giants are also focusing on developing novel next generation antibody products for the treatment of leukemia in order to maintain their competitive advantage and penetrate new regional markets.

Contents

1. RESEARCH METHODOLOGY

2. GLOBAL LEUKEMIA ANTIBODY MARKET OVERVIEW

- 2.1 Current Market Scenario
- 2.2 Regional Market Analysis
- 2.3 Future Market Opportunity

3. GLOBAL LEUKEMIA ANTIBODIES CLINICAL TRIALS OVERVIEW

- 3.1 By Company
- 3.2 By Country
- 3.3 By Phase
- 3.4 By Patient Segment

4. LEUKEMIA ANTIBODY DRUG CONJUGATES INSIGHT

- 4.1 Overview
- 4.2 Drugs Availability, Patent, Price & Dosage Analysis

5. LEUKEMIA MONOCLONAL ANTIBODY INSIGHT

- 5.1 Overview
- 5.2 Drugs Availability, Patent, Price & Dosage Analysis

6. LEUKEMIA BISPECIFIC ANTIBODY INSIGHT

- 6.1 Overview
- 6.2 Drugs Availability, Patent, Price & Dosage Analysis

7. GLOBAL LEUKEMIA ANTIBODIES – GLOBAL & REGIONAL SALES ANALYSIS

- 7.1 Besponsa
- 7.2 Rituxan
- 7.3 Gazyva
- 7.4 Blincyto

8. GLOBAL LEUKAEMIA ANTIBODIES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

- 8.1 Research
- 8.2 Preclinical
- 8.3 Phase-I
- 8.4 Phase-I/II
- 8.5 Phase-II
- 8.6 Phase-III
- 8.7 Preregistration
- 8.8 Registered

9. MARKETED LEUKAEMIA ANTIBODIES CLINICAL, PATENT & ORPHAN DESIGNATION INSIGHT

10. COMPETITIVE LANDSCAPE

- 10.1 Amgen
- 10.2 Amphivena Therapeutics
- 10.3 AstraZeneca
- 10.4 Eli Lilly
- 10.5 GlaxoSmithKline
- 10.6 Innovent
- 10.7 Janssen Pharmaceuticals
- 10.8 Jasper Therapeutics
- 10.9 Pfizer
- 10.10 Roche

List Of Figures

LIST OF FIGURES

Figure 2-1: Global – Leukemia Incidences & Deaths, 2020 & 2030

Figure 2-2: Global – Leukemia Antibodies Therapeutics Market Size (US\$ Billion), 2018 - 2021

Figure 2-3: Global – Leukemia Antibodies Therapeutics Market Size by Type (US\$ Million), 2021

Figure 2-4: Global – Leukemia Antibodies Therapeutics Market Size by Type (%), 2021

Figure 2-5: Global – Leukemia Antibodies Therapeutics Market Size by Region (US\$ Billion), 2021

Figure 2-6: Global – Leukemia Antibodies Therapeutics Market Size by Region (%), 2021

Figure 2-7: Global – Leukemia Antibody Therapeutics Market Size (US\$ Billion), 2022 - 2028

Figure 2-8: US – Leukemia Antibody Therapeutics Market Size (US\$ Billion), 2022 - 2028

Figure 2-9: Europe – Leukemia Antibody Therapeutics Market Size (US\$ Billion), 2022 - 2028

Figure 2-10: China – Leukemia Antibody Therapeutics Market Size (US\$ Billion), 2022 - 2028

Figure 2-11: Japan – Leukemia Antibody Therapeutics Market Size (US\$ Billion), 2022 - 2028

Figure 3-1: Global - Leukemia Antibodies in Clinical Trials by Company, 2022 till 2028

Figure 3-2: Global - Leukemia Antibodies in Clinical Trials by Company, 2022 till 2028

Figure 3-3: Global - Leukemia Antibodies in Clinical Trials by Phase, 2022 till 2028

Figure 3-4: Global - Leukemia Antibodies in Clinical Trials by Patient Segment, 2022 till 2028

Figure 4-1: Mylotarg – FDA Approval, Withdrawal & Re-Approval Year

Figure 4-2: Mylotarg – Approval Year by Region

Figure 4-3: UK - Cost of Supply of Mylotarg 5mg Intravenous Powder (GBP/US\$), May'2022

Figure 4-4: Mylotarg - Cost of Supply of Vial for Injection by Region (US\$), May'2022

Figure 4-5: Mylotarg – Number of Induction Cycle & Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML

Figure 4-6: Mylotarg – Cost of Induction Cycle, Consolidation Cycles & Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US\$), May'2022

Figure 4-7: Mylotarg – Recommended Number of Induction & Continuation Cycle for

Treatment of Newly Diagnosed CD-33 Positive AML

Figure 4-8: Mylotarg – Length of Induction & Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days)

Figure 4-9: Mylotarg – Recommended Dose of Initial Dose & Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m²)

Figure 4-10: Mylotarg – Cost of Induction Phase & Continuation Phase & Full Treatment Cost of CD-33 positive AML (US\$), May'2022

Figure 4-11: Mylotarg – Cost of Single Dose & Full Treatment Cost of Relapsed & Refractory CD33 Positive AML, May'2022

Figure 4-12: Besponsa - Approval Year by Region

Figure 4-13: UK - Cost of Supply of Besponsa 0.9mg Intravenous Powder (GBP/US\$), May'2022

Figure 4-14: Besponsa - Cost of Supply of Vial for Injection by Region (US\$), May'2022

Figure 4-15: Besponsa – Duration of Initial Treatment Cycle & Subsequent Cycles (Days)

Figure 4-16: Besponsa – Recommended Dose for 1st, 8th & 15th Day of Initial Treatment Cycle (mg/m²)

Figure 4-17: Besponsa – Cost of Single Unit & Full Cost of Initial Treatment Cycle (US\$), May'2022

Figure 4-18: Besponsa – Duration of Treatment of ALL – After & Without HSCT (Weeks)

Figure 4-19: Lumoxiti – Year of Orphan Designation, FDA Approval & Patent Expiration

Figure 4-20: Lumoxiti – Duration of Single Treatment Cycle & Full Treatment (Weeks)

Figure 4-21: Lumoxitin – Cost of Single Dose, Single Treatment Cycle & Full Treatment of Hairy Cell Leukemia (US\$), May'2022

Figure 5-1: Rituxan – FDA Approval Year by Indication

Figure 5-2: MabThera – Approval Year by Region

Figure 5-3: US– Price for a Supply of 10 ml & Price Per ml of Rituxan Solution for Injection (US\$), May'2022

Figure 5-4: US – Price for a Supply of 50 ml & Price Per ml of Rituxan Solution for Injection (US\$), May'2022

Figure 5-5: US – Price for a Supply of 100 ml & Price Per ml of Solution Rituxan for Injection (US\$), May'2022

Figure 5-6: UK - Price for a Supply of 10 ml & Price Per ml of Rituxan Solution for Injection (GBP/US\$), May'2022

Figure 5-7: UK - Price for a Supply of 50 ml & Price Per ml of Rituxan Solution for Injection (GBP/US\$), May'2022

Figure 5-8: Rituxan – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US\$), May'2022

Figure 5-9: Truxima – Price for a Supply of 10 ml & Price Per ml of Solution for Injection

(US\$), May'2022

Figure 5-10: Truxima – Price for a Supply of 50 ml & Price Per ml of Solution for Injection (US\$), May'2022

Figure 5-11: UK – Cost of 50ml Truxima 500mg/50ml Solution & Per Unit Cost of Solution (GBP/US\$), May'2022

Figure 5-12: UK – Cost of 2 Vials of Truxima 100mg/10ml Solution & Per Unit Cost of Vial (GBP/US\$), May'2022

Figure 5-13: Truxima – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US\$), May'2022

Figure 5-14: Riabni – Cost of Supply of 10ml & Per Unit Price of 10mg/ml Intravenous Solution (US\$), May'2022

Figure 5-15: Riabni – Cost of Supply of 50ml & Per Unit Price of 10mg/ml Intravenous Solution (US\$), May'2022

Figure 5-16: Riabni – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US\$), May'2022

Figure 5-17: Ruxience – Approval Year by Region

Figure 5-18: US – Cost of Supply of 10ml & Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US\$), May2022

Figure 5-19: US – Cost of Supply of 50ml & Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US\$), May2022

Figure 5-20: UK – Cost of 50ml Ruxience 500mg/50ml Solution & Per Unit Cost of Solution (GBP/US\$), May'2022

Figure 5-21: UK – Cost of 10ml Ruxience 100mg/10ml Solution & Per Unit Cost of Solution (GBP/US\$), May'2022

Figure 5-22: Riabni – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US\$), May'2022

Figure 5-23: Rituxan Hycela – Price for 11.7 ml Supply & Price Per ml of 23,400 units-1,400mg/11.7 ml Subcutaneous Solution (US\$), May'2022

Figure 5-24: Rituxan Hycela – Price for 13.4 ml Supply & Price Per ml of 26,800 units-1,600 mg/13.4ml Subcutaneous Solution (US\$), May'2022

Figure 5-25: Rituxan Hycela – Duration of CLL Treatment (Weeks)

Figure 5-26: Rituxan Hycela - Cost of Single Treatment Cycle & Full Treatment of CLL (US\$), May'2022

Figure 5-27: Gazyva – Approval Year by Cancer Type

Figure 5-28: Gazyva – Price for 40ml Supply & Price Per ml of Intravenous Solution (US\$), May'2022

Figure 5-29: Gazyva – Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg)

Figure 5-30: Gazyva – Duration of Single Treatment Cycle & Full Treatment of CLL

(Week)

Figure 5-31: Gazyva – Cost of Initial & Subsequent Treatment Cycle & Full Treatment Cost of CLL (US\$), February'2022

Figure 5-32: Arzerra – Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US\$), May'2022

Figure 5-33: Arzerra – Price for a Supply of 50 ml & Price Per ml of Intravenous Solution (US\$), May'2022

Figure 5-34: Arzerra – Initial & Maintenance Dose for Previously Untreated CLL (mg)

Figure 5-35: Arzerra – Minimum & Maximum Treatment Duration for Previously Untreated CLL (Weeks)

Figure 5-36: Arzerra – Minimum & Maximum Treatment Cost for Previously Untreated CLL (US\$), May'2022

Figure 5-37: Arzerra – Initial & Maintenance Dose for Relapsed CLL (mg)

Figure 5-38: Arzerra – Minimum & Maximum Treatment Cost for Relapsed CLL (US\$), May'2022

Figure 5-39: Arzerra – Initial & Maintenance Dose for Refractory CLL (mg)

Figure 5-40: Arzerra – Treatment Duration for Refractory CLL (Weeks)

Figure 5-41: Arzerra – Minimum & Maximum Treatment Cost for Refractory CLL (US\$), May'2022

Figure 6-1: Blincyto - Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL

Figure 6-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days)

Figure 6-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-cell precursor ALL (US\$), May'2022

Figure 6-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL

Figure 6-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)

Figure 6-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US\$), February'2022

Figure 7-1: Besponsa – Quarter 1 Sales by Region (US\$ Million), 2022

Figure 7-2: Besponsa – Quarter 1 Sales by Region (%), 2022

Figure 7-3: Global - Besponsa Annual Sales (US\$ Million), 2020 & 2021

Figure 7-4: Global - Besponsa Quarterly Sales (US\$ Million), 2020 & 2021

Figure 7-5: US - Besponsa Quarterly Sales (US\$ Million), 2020 & 2021

Figure 7-6: Europe - Besponsa Quarterly Sales (US\$ Million), 2020 & 2021

Figure 7-7: ROW - Besponsa Quarterly Sales (US\$ Million), 2020 & 2021

Figure 7-8: Besponsa - Annual Sales by Region (US\$ Million), 2020 & 2021

- Figure 7-9: Besponsa - Quarterly Sales by Region (%), 2020
- Figure 7-10: Besponsa - Quarterly Sales by Region (%), 2021
- Figure 7-11: Rituxan – Quarter -1 Value by Region (US\$/CHF Million), 2022
- Figure 7-12: Global - Rituxan Annual Sales Value (US\$/CHF Million), 2018 - 2021
- Figure 7-13: US - Rituxan Annual Sales Value (US\$/CHF Million), 2018 - 2021
- Figure 7-14: Europe - Rituxan Annual Sales Value (US\$/CHF Million), 2018 - 2021
- Figure 7-15: Japan - Rituxan Annual Sales Value (US\$/CHF Million), 2018 - 2021
- Figure 7-16: ROW - Rituxan Annual Sales Value (US\$/CHF Million), 2018 - 2021
- Figure 7-17: Rituxan - Annual Sales Value by Region (US\$/CHF Million), 2021
- Figure 7-18: Rituxan - Annual Sales Value by Region (%), 2021
- Figure 7-19: Global - Rituximab Quarterly Sales Value (US\$ Billion), 2021
- Figure 7-20: Global - Rituxan Quarterly Sales Value (US\$ Million), 2020
- Figure 7-21: Gazyva – Quarter -1 Value by Region (US\$/CHF Million), 2022
- Figure 7-22: Global - Gazyva Annual Sales Value (US\$/CHF Million), 2018 - 2021
- Figure 7-23: US - Gazyva Annual Sales Value (US\$/CHF Million), 2019 - 2021
- Figure 7-24: Europe - Gazyva Annual Sales Value (US\$/CHF Million), 2019 - 2021
- Figure 7-25: Japan - Gazyva Annual Sales Value (US\$/CHF Million), 2019 - 2021
- Figure 7-26: ROW - Gazyva Annual Sales Value (US\$/CHF Million), 2019 - 2021
- Figure 7-27: Gazyva - Annual Sales Value by Region (US\$/CHF Million), 2021
- Figure 7-28: Gazyva - Annual Sales Value by Region (%), 2021
- Figure 7-29: US - Gazyva Quarterly Sales Value (US\$ Billion), 2021
- Figure 7-30: US - Gazyva Quarterly Sales Value (US\$/CHF Million), 2020
- Figure 7-31: Blincyto – Quarter 1 Sales by Region (US\$ Million), 2022
- Figure 7-32: Blincyto – Quarter 1 Sales by Region (%), 2022
- Figure 7-33: Blincyto – Sales Value (US\$ Million), 2018 - 2021
- Figure 7-34: US – Blincyto Sales Value (US\$ Million), 2018 - 2021
- Figure 7-35: ROW – Blincyto Sales Value (US\$ Million), 2018 - 2021
- Figure 7-36: Global – Blincyto Quarterly Sales Value (US\$ Millions), Q1-Q4'2021
- Figure 7-37: US – Blincyto Quarterly Sales Value (US\$ Millions), Q1-Q4'2021
- Figure 7-38: ROW – Blincyto Quarterly Sales Value (US\$ Millions), Q1-Q4'2021
- Figure 7-39: Blincyto – Annual Sales Value by Region (US\$ Million), 2021
- Figure 7-40: Blincyto - Annual Sales Value by Region (%), 2021

I would like to order

Product name: Global Leukemia Antibodies Market, Drug Sales & Clinical Trials Insight 2028

Product link: <https://marketpublishers.com/r/GA589F953407EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA589F953407EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970